Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alnylam Pharmaceuticals (NQ: ALNY ) 237.83 +1.13 (+0.48%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Alnylam Pharmaceuticals < Previous 1 2 3 4 5 Next > Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results July 18, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations June 24, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Issues 2023 Corporate Responsibility Report May 07, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity May 02, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results April 18, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension April 07, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session March 20, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease March 13, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives March 05, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam to Webcast Presentations at Upcoming March Investor Conferences February 27, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity February 15, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results January 29, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association January 09, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates January 07, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day December 13, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire 3 biotech powerhouses poised to thrive amid sector rebound December 08, 2023 If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader. Via MarketBeat Topics ETFs Alnylam to Webcast Virtual R&D Day December 06, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023 November 30, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk November 11, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shareholder Alert: Investigation over Possible Violations of Securities Laws November 08, 2023 San Diego, CA -- (SBWIRE) -- 11/08/2023 -- Alnylam Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements. Via SBWire Alnylam to Webcast Presentations at Upcoming November Investor Conferences November 07, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity November 02, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year October 26, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine October 25, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy October 25, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results October 19, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis October 09, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023 October 06, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Argenx's 28% Surge & Promising Product Propel Investor Confidence September 25, 2023 Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. Via MarketBeat < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.